Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Boehringer Ingelheim
Mallinckrodt
Medtronic

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR BRIGATINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Brigatinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01449461 ↗ A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Completed Ariad Pharmaceuticals Phase 1/Phase 2 2011-09-20 The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer (NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.
NCT02094573 ↗ A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Completed Ariad Pharmaceuticals Phase 2 2014-06-04 The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
NCT02706626 ↗ Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Recruiting Academic Thoracic Oncology Medical Investigators Consortium Phase 2 2017-03-09 The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
NCT02706626 ↗ Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Recruiting Ariad Pharmaceuticals Phase 2 2017-03-09 The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
NCT02706626 ↗ Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Recruiting Duke University Phase 2 2017-03-09 The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
NCT02706626 ↗ Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Recruiting Georgetown University Phase 2 2017-03-09 The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brigatinib

Condition Name

Condition Name for Brigatinib
Intervention Trials
Lung Cancer 5
Non-small Cell Lung Cancer 5
Advanced Malignancies 4
Non Small Cell Lung Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brigatinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 17
Lung Neoplasms 13
Neoplasms 7
Carcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brigatinib

Trials by Country

Trials by Country for Brigatinib
Location Trials
United States 107
Japan 24
Spain 23
France 22
Italy 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brigatinib
Location Trials
California 11
Colorado 7
Texas 6
Minnesota 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brigatinib

Clinical Trial Phase

Clinical Trial Phase for Brigatinib
Clinical Trial Phase Trials
Phase 3 2
Phase 2 16
Phase 1/Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brigatinib
Clinical Trial Phase Trials
Recruiting 13
Not yet recruiting 4
Completed 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brigatinib

Sponsor Name

Sponsor Name for Brigatinib
Sponsor Trials
Ariad Pharmaceuticals 8
Takeda 8
National Cancer Institute (NCI) 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brigatinib
Sponsor Trials
Other 28
Industry 20
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Boehringer Ingelheim
McKesson
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.